These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 8450215

  • 21. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY.
    J Immunol; 1989 Jun 15; 142(12):4441-9. PubMed ID: 2786033
    [Abstract] [Full Text] [Related]

  • 22. Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens.
    Afrin F, Ali N.
    J Parasitol; 1998 Aug 15; 84(4):743-8. PubMed ID: 9714204
    [Abstract] [Full Text] [Related]

  • 23. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.
    Stern JJ, Oca MJ, Rubin BY, Anderson SL, Murray HW.
    J Immunol; 1988 Jun 01; 140(11):3971-7. PubMed ID: 3131421
    [Abstract] [Full Text] [Related]

  • 24. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 25. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC.
    J Parasitol; 2010 Oct 28; 96(5):929-36. PubMed ID: 20950100
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A.
    J Immunol; 2009 Jul 01; 183(1):470-9. PubMed ID: 19542458
    [Abstract] [Full Text] [Related]

  • 29. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG.
    J Immunol; 1998 Dec 01; 161(11):6171-9. PubMed ID: 9834103
    [Abstract] [Full Text] [Related]

  • 30. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, García-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E.
    Infect Immun; 2005 Feb 01; 73(2):812-9. PubMed ID: 15664920
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P, Sukumaran B, Saxena S, Madhubala R.
    Vaccine; 2004 Aug 13; 22(23-24):3053-60. PubMed ID: 15297055
    [Abstract] [Full Text] [Related]

  • 34. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR, Kaufmann D, Campos-Neto A, Reed SG.
    J Immunol; 1996 Dec 01; 157(11):5034-41. PubMed ID: 8943412
    [Abstract] [Full Text] [Related]

  • 35. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S.
    Vaccine; 2008 Oct 29; 26(46):5822-9. PubMed ID: 18804512
    [Abstract] [Full Text] [Related]

  • 36. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P, Saxena S, Madhubala R.
    Vaccine; 2006 Mar 20; 24(13):2409-16. PubMed ID: 16413950
    [Abstract] [Full Text] [Related]

  • 37. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
    Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, Dube A.
    Vaccine; 2008 Oct 23; 26(45):5700-11. PubMed ID: 18762224
    [Abstract] [Full Text] [Related]

  • 38. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R, Kaur S.
    Vaccine; 2010 May 21; 28(23):4002-12. PubMed ID: 20093205
    [Abstract] [Full Text] [Related]

  • 39. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R, Das P, De T, Chakraborti T.
    Immunobiology; 2013 Jan 21; 218(1):114-26. PubMed ID: 22440312
    [Abstract] [Full Text] [Related]

  • 40. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A, Jaafari MR, Khamesipour A.
    Exp Parasitol; 2007 Feb 21; 115(2):127-34. PubMed ID: 16979165
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.